Jerel Davis, PhD

Managing Director, Versant Ventures

Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.

+ Show More

Todd Foley

Managing Director, MPM Capital

Todd is a Managing Director at MPM Capital. He focuses on biotech investments, and in addition to serving on Repare’s board, he serves on a number of MPM portfolio company boards, including Switch Bio, Chiasma (CHMA), ClinicalInk, Iconic, Rhythm, Semma and Tetherex.

+ Show More

Briggs W. Morrison, MD

CEO, Syndax Pharmaceuticals

Briggs is the CEO of Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.

+ Show More

Lloyd M. Segal

President & CEO, Repare Therapeutics

In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.

+ Show More